[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.171.35. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Download PDF
Table. 
Patient Response Summary
Patient Response Summary
1.
Weaver  JWilly  MAvigan  M Informatic tools and approaches in postmarketing pharmacovigilance used by the FDA. AAPS J 2008;10 (1) 35- 41
PubMedArticle
2.
Wysowski  DKChang  JT Alendronate and risendronate: reports of severe bone, joint and muscle pain. Arch Intern Med 2005;165 (3) 346- 347
PubMedArticle
3.
US Food and Drug Administration, Information on bisphosphonates. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm101551.htm. Accessed December 15, 2008
4.
Golomb  BA McGraw  JJEvans  MADimsdale  JE Physician response to patient reports of adverse drug effects: implication for patient targeted adverse effect surveillance. Drug Saf 2007;30 (8) 669- 675
PubMedArticle
Research Letters
June 22, 2009

Patient- and Physician-Oriented Web Sites and Drug Surveillance: Bisphosphonates and Severe Bone, Joint, and Muscle Pain

Arch Intern Med. 2009;169(12):1164-1166. doi:10.1001/archinternmed.2009.133

Postmarketing surveillance and the determination of the real-world safety profile of prescription drugs is arguably flawed. Recent identification of significant adverse effects associated with newly approved prescription drugs support the sometimes-held view that a new system needs to be introduced. The present voluntary system has not provided a sufficient early warning system, and some have called for active systems that probe for potential adverse effects of approved prescription drugs.1 Patient-oriented Web sites may provide an opportunity to identify potential adverse effects early in a drug's postmarket history.

In 2005, Wysowski and Chang2 published a letter regarding a series of case reports submitted to the Food and Drug Administration (FDA) on severe bone, joint, and muscle pain associated with the use of alendronate sodium and risedronate sodium for 1995 to 2002. In all, 116 case reports of serious adverse events were voluntarily submitted. A subsequent FDA Alert was issued on January 2008 concerning serious and sometimes incapacitating bone, joint, and muscle pain associated with bisphosphonate use.3 One such case was seen at Massachusetts General Hospital, prompting an investigation into the literature on the topic. The patient pointed us to a patient-oriented Web site called “Askapatient” (http://www.askapatient.com) that noted multiple case reports of the development of an influenzalike syndrome early in the treatment with bisphosphonate drugs and subsequent severe and sometimes incapacitating joint, bone, and muscle pain. The site posts comments from patients on their experiences with prescription drugs and asks them to rate the drug using a scale of 1 (poor) to 5 (excellent). Several patient reports indicated a persistence of symptoms for months.

We approached the site administrator and obtained permission to post a survey (using SurveyMonkey.com) on the site that was specific to the question of joint, bone, and muscle pain with bisphosphonate use. The survey went live in late October 2008 and was taken down in late January 2009. The results of the survey are provided in the Table.

A physician community–based Web site (http://www.sermo.com) was also reviewed simultaneous to the posting of the survey at Askapatient. One case of an influenzalike syndrome with joint, bone, and muscle pain was posted by a physician. Importantly, when asked if this adverse event had been seen by other clinicians, 63% of the respondents indicated it had not. This number is in keeping with the patient experience noted by Askapatient respondents when queried concerning their prescriber's impression that bisphosphonate use was not a possible cause of the symptoms. Golomb and colleagues4 previously noted this lack of appropriate attribution on the part of clinicians to muscle pain and the use of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors.

User-submitted reviews are commonplace in most commercial domains. Health care has been a notable exception. Web sites such as Askapatient provide a window into the patient experience and a potential resource for developing a better understanding of the true adverse effect profile of prescription drugs. Probing sites such as Askapatient or Sermo does not equate to true pharmacovigilance. These sites and others may provide a unique window into the drug therapy experience from both the prescriber and patient/consumer perspective. Causality, incidence, and confounders cannot be identified with such probing. The value of such sites has yet to be explored in health care. Given the poor showing of the existing voluntary reporting system, probing user and provider community Web sites may provide a valuable tool.

Back to top
Article Information

Correspondence: Mr DeMonaco, Massachusetts General Hospital, 101 Merrimac St, Ste 710, Boston, MA 02114 (hdemonaco@partners.org).

Financial Disclosure: None reported.

References
1.
Weaver  JWilly  MAvigan  M Informatic tools and approaches in postmarketing pharmacovigilance used by the FDA. AAPS J 2008;10 (1) 35- 41
PubMedArticle
2.
Wysowski  DKChang  JT Alendronate and risendronate: reports of severe bone, joint and muscle pain. Arch Intern Med 2005;165 (3) 346- 347
PubMedArticle
3.
US Food and Drug Administration, Information on bisphosphonates. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm101551.htm. Accessed December 15, 2008
4.
Golomb  BA McGraw  JJEvans  MADimsdale  JE Physician response to patient reports of adverse drug effects: implication for patient targeted adverse effect surveillance. Drug Saf 2007;30 (8) 669- 675
PubMedArticle
×